Indole Hallucinogens as Animal Models of Schizophrenia

  • Edward F. Domino


To say the least, the literature on indole hallucinogens and schizophrenia is confusing. This is because investigators who have access to schizophrenic patients do not have sophisticated gas chromatographic and mass spectrographic facilities, and those chemically sophisticated researchers who have such analytic facilities do not have access to a suitable patient research population. This situation has existed for some time and probably will continue to exist for a long time. The current nature of psychiatric research strategy, funding, social and legal pressures regarding informed consent and commitment of the mentally ill all combine to retard progress. This situation has become so confusing in the State of Michigan in the last two years that most research with mental patients has stopped. In attempting to protect the rights of the mentally ill, their rights to proper diagnoses and better treatments are being discarded.


Schizophrenic Patient Rabbit Lung Chronic Schizophrenic Patient Lysergic Acid Diethylamide Aromatic Amino Acid Decarboxylase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adams, R. L. P. Delayed methylation of DNA in developing sea urchin embryos. Nature (New Biol.), 1973, 244:131, 27–29.Google Scholar
  2. Aghajanian, G. K., & Freedman, D. X. Biochemical and morphological aspects of LSD pharmacology. In D. H. Efron (Ed.), Psychopharmacology—A Review of Progress 1957–1967, PHSP #1836. Superintendent of Documents, Washington, D.C., 1968, pp. 1185-1193.Google Scholar
  3. Aghajanian, G. K., Sheard, M. H., & Foote, W. E. LSD and mescaline: comparison of effects on single units in the midhrain raphé. In D. H. Efron (Ed.), Psychotomimetic Drugs, New York: Raven Press, 1970, pp. 165–170.Google Scholar
  4. Ahn, H. A., Walker, R. W., VandenHeuvel, W. J. A., Rosegay, A., & Mandel, L. R. Studies on the in vivo biosynthesis of N, N-dimethyltryptamine (DMT) in the rabbit and rat. Fed. Proc. 1973, 32, 511.Google Scholar
  5. Alexander, F., Curtis, G. C., III, Sprince, H. & Crosley, A. P., Jr. l-Methionine and l-tryptophan feedings in non-psychotic and schizophrenic patients with and without tranylcypromine. J. Nerv. Ment. Dis., 1963, 137, 135–142.PubMedCrossRefGoogle Scholar
  6. Appel, J. B. The effects of “psychotomimetic” drugs on animal behavior. In D. H. Efron (Ed.), Pharmacology—A Review of Progress 1957–1967, PHSP #1836, Superintendent of Documents, Washington, D.C., 1968, pp. 1211-1222.Google Scholar
  7. Axelrod, J. The enzymatic N-methylation of serotonin and other amines. J. Pharmacol. Exp. Ther. 1962, 138, 28–33.PubMedGoogle Scholar
  8. Ban, T. Monoamine oxidase inhibitor antidepressants, In Psychopharmacology. Baltimore: Williams and Wilkins, 1969.Google Scholar
  9. Banarjee, S. P. & Snyder, S. H. Methyltetrahydrofolic acid mediates N- and O-methylation of biogenic amines. Science 1973, 182, 74–75.CrossRefGoogle Scholar
  10. Barchas, J. D., Elliott, G. R., DoAmaral, J., Erdelyi, E., O’Connor, S., Bowden, M., Brodie, H. K. H., Berger, P. A., Renson, J., & Wyatt, R. J. Triptolines: Formation from tryptamines and 5-MTHF by human platelets. Arch. Gen. Psychiat. 1974, 31, 862–867.PubMedCrossRefGoogle Scholar
  11. Bidder, T. G., Mandel, L. R., Ahn, H. S., Walker, R. W., & VandenHeuvel, W. J. A. Blood and urinary DMT concentrations in acute psychotic disorders. Lancet, 1974, 1, 165.PubMedCrossRefGoogle Scholar
  12. Bishop, P. O., Burke, W., & Hayhow, W. R. Lysergic acid diethylamide block of lateral geniculate synapses and relief by repetitive stimulation. Exp. Neurol. 1959, 1, 556–568.PubMedCrossRefGoogle Scholar
  13. Bishop, P. O., Field, G., Hennessy, B. L., & Smith, J. R. Actions of d-lysergic acid diethylamide on lateral geniculate synapses. J. Neurophysiol, 1958, 21, 529–549.PubMedGoogle Scholar
  14. Borella, L., Herr, F., & Wojdan, A. Prolongation of certain effects of amphetamine by chlorpromazine. Canad. J. Physiol and Pharmacol., 1969, 47, 7–13.CrossRefGoogle Scholar
  15. Bovet, D., & Gatti, G. L. Pharmacology of instrumental avoidance conditioning. In Proceedings of 2nd International Pharmacological Meeting, Prague, 1965, pp. 75-89.Google Scholar
  16. Caldwell, D. F., Oberleas, D., Clancy, J. J., & Praasad, A. A. Behavioral impairment in adult rats following acute zinc deficiency. Proc. Soc. Exp. Biol. Med., 1970, 133, 1417–1421.PubMedGoogle Scholar
  17. Cohen, I. & Vogel, W. H. Determination and physiological disposition of dimethyltryptamine in rat brain, liver and plasma. Biochem. Pharmacol., 1972, 21, 1214–1218.PubMedCrossRefGoogle Scholar
  18. Coward, J. K., D’Urso-Scott, M.,& Sweet, W. D. Inhibition of catechol-O-methyltransferase by S-adenosylhomocysteine and S-adenosylhomocysteine sulfoxide, a potential transition-state analog. Biochem. Pharmacol., 1972, 21, 1200–1203.PubMedCrossRefGoogle Scholar
  19. Deguchi, T., & Barchas, J. Inhibitions of transmethylations of biogenic amines by S-adenosylhomocysteine. J. Biol. Chem., 1972. 246, 3175–3181.Google Scholar
  20. Domino, E. F., Krause, R. R., & Bowers, J. Various enzymes involved with putative neuro-transmitters —regional distribution in the brain of deceased mentally normal, chronic schizophrenics or organic brain syndrome patients. Arch. Gen. Psychiat., 1973, 29, 195–201.PubMedCrossRefGoogle Scholar
  21. Domino, E. F., & Krause, R. R. Plasma tryptophan tolerance curves in drug free normal controls, schizophrenic patients and prisoner volunteers. J. Psychiat. Res., 1974a, 10, 247–261.PubMedCrossRefGoogle Scholar
  22. Domino, E. F., & Krause, R. R. Unpublished observations, 1974b.Google Scholar
  23. Domino, E. F., & Luby, E. D. Abnormal mental states induced by phencyclidine as a model of schizophrenia. In J. O. Cole, A. Friedhoff, and A. M. Friedman (Eds.), Psychopathology and Psychopharmacology, Proc. 62 Meeting of Amer. Psychopath. Assoc., Baltimore: Johns Hopkins Press, 1973, pp. 35–50.Google Scholar
  24. Domino, E. F., & Lutz, M. F. Unpublished observations, 1974.Google Scholar
  25. Domino, E. F., & Sampath-Khanna, S. Decreased platelet MAO in chronic schizophrenics. Amer. J. Psychiat, 1975, in press.Google Scholar
  26. Evarts, E. V. Effects of a series of indoles on synaptic transmission in the lateral geniculate nucleus of the cat. In H. H. Pennes (Ed.), Progress in Neurobiology, III-Psychopharmacology, New York, Hoeber-Harper, 1958, pp. 173-194.Google Scholar
  27. Evarts, E. V., Landau, W., Freygang, W., Jr., & Marshall, W. H. Some effects of lysergic acid diethylamide and bufotenine on electrical activity in the cat’s visual system. Am. J. Physiol., 1955. 182, 594–598.PubMedGoogle Scholar
  28. Fisher, R. Chemistry of the brain. Nature 1968, 220, 411.CrossRefGoogle Scholar
  29. Franzen, Fr., & Gross, H. Tryptamine, N, N-dimethyltryptamine, N, N-dimethyl-5-hydroxy-tryptamine and 5-methoxytryptamine in human blood and urine. Nature, 1965, 206, 1052.PubMedCrossRefGoogle Scholar
  30. Gillin, J. C., Cannon, E., Magyar, R., Schwartz, M., & Wyatt, R. J. Failure of DMT to evoke tolerance in cats. Biol. Psychiat., 1973, 7, 213–220.PubMedGoogle Scholar
  31. Gilmour, D. C., Manowitz, P., Frosch, W. A., & Shopsin, B. Association of plasma tryptophan levels with clinical change in female schizophrenic patients. Biol. Psychiat., 1973, 6, 119.PubMedGoogle Scholar
  32. Greenberg, R. N, N-Dimethylated and N, N-diethylated indoleamines in schizophrenia. In H. C. Sabelli (Ed.), Chemical Modulation of Brain Function—A tribute to J. E. P. Toman, New York, Raven Press, 1973, pp. 277–2Google Scholar
  33. Gross, V. H., & Franzen, Fr. Zur bestimmung korpereigener amine in biologischen substraten. Zeitschrift für Klinische Chemie, 1965, 3, 99–102.Google Scholar
  34. Heath, R. G., Vesselhof, W., Bishop, N. P., & Byers, L. W. Behavioral and metabolic changes associated with administration of tetraethylthiuram disulfide. Dis. Nerv. System 1965, 26, 99–106.Google Scholar
  35. Himwich, H. E. (Ed.) Biochemistry, Schizophrenias and Affective Illnesses, Baltimore: Williams and Wilkins, 1971.Google Scholar
  36. Himwich, H. E., Narashimhachari, N., Heller, B., Spaide, J., Haskovec, L., Fujimori, M., & Tabushi, K. Biochemical approaches to the study of schizophrenia. In H. C. Sabelli (Ed.), Chemical Modulations of Brain Function—A Tribute to J. E. P. Toman, New York: Raven Press, 1973.Google Scholar
  37. Hoffer, A., Osmond, H., Callbeck, M. J., & Kahan, I. Treatment of schizophrenia with nicotinic acid and nicotinamide. J. Clin. Exp. Psychopath., 1957, 18, 131–158.PubMedGoogle Scholar
  38. Holmstedt, B., & Lindgren, J. B. Chemical constituents and pharmacology of South American snuffs. In D. H. Efron (Ed.), Ethnopharmacologic Search for Psychoactive Drugs, Publication No. 1645, Public Health Service, Washington, D.C.,1967, pp. 339-382.Google Scholar
  39. Horita, A., & Hamilton, A. E. Lysergic acid diethylamide: Dissociation of its behavioral and hyperthermic actions by DL-alpha-methyl-p-tyrosine. Science, 1969, 164, 78.PubMedCrossRefGoogle Scholar
  40. Hsu, L. L., & Mandell, A. J. Multiple N-methyltransferases for aromatic alkylamines in brain. Life Sci., 1973, 13, 847–868.PubMedCrossRefGoogle Scholar
  41. Isbell, H. Quoted in D. H. Efron (Ed.), Ethnopharmacologic Search for Psychoactive Drugs, Publication No. 1645, Public Health Service, Washington, D. C., 1967, p. 369.Google Scholar
  42. Juntunen, J. M., Struck, W. G., Warner, K. A., Frohman, C. E., & Gottlieb, J. S. Effects of tryptophan loading on indole metabolite levels in blood and urine of schizophrenic patients. Biol. Psychiat., 1974, in press.Google Scholar
  43. Kaplan, J., Mandel, L. R., Stillman, R., Walker, R. W., VandenHeuvel, W. J. A., Gillin, J. C. & Wyatt, R. J. Blood and urine levels of N, N-dimethyltryptamine following administration of psychoactive dosages to human subjects. Psychopharmacologia, 1974, 38, 239–245.PubMedCrossRefGoogle Scholar
  44. Kerr, S. J. Competing methyltransferase systems. J. Biol. Chem. 1972, 247, 4248–4252.PubMedGoogle Scholar
  45. Koella, W. P. Neurophysiological effects of psychotomimetic substances (A supplemental review). In D. H. Efron (Ed.), Psychopharmacology—A Review of Progress 1957–1967, PHSP #1836, Superintendent of Documents, Washington, D.C., 1968, pp. 1223-1230.Google Scholar
  46. Koella, W. P., Beaulieu, R. F., & Bergen, J. R. Stereotyped behavior and cyclic changes in response produced by LSD in goats. Int. J. Neuropharmacol., 1964, 3, 397–403.PubMedCrossRefGoogle Scholar
  47. Kovacic, B., & Domino, D. F. Effects of various drugs on DMT-induced disruption of rat bar pressing behavior. The Pharmacologist, 1973, 15, 218.Google Scholar
  48. Kovacic, B. & Domino, E. F. Tolerance to behavioral effects of dimethyltryptamine (DMT) in the rat. Fed. Prod., 1974, 33, 549.Google Scholar
  49. Krause, R. & Domino, E. F. Kinetics of product inhibition of rabbit lung N-methyltransferase. Res. Comm. Chem. Path. and Pharmacol. 1974, 9:2, 399–373.Google Scholar
  50. Lal, S., & Sourkes, T. L. Effect of various chlorpromazine metabolites in amphetamine-induced stereotyped behavior in the rat. Europ. J. Pharmacol., 1972. 1 7, 283–286.CrossRefGoogle Scholar
  51. Lin, R. L., Narasimhachari, N., & Himwich, H. E. Inhibition of indolethylamine-N-methyl-transferase by S-adenosylhomocysteine. Biochem. Biophys. Res. Comm. 1973, 54, 751–759.PubMedCrossRefGoogle Scholar
  52. Lipinski, J., Mandel, L. R., Ahn, H. S., VandenHeuvel, W. J. A., & Walker, R. W. Blood dimethyltryptamine concentrations in psychotic disorders. Biol. Psychiat., 1974, 9:1, 89–91.PubMedGoogle Scholar
  53. Lu, L. W., Wilson, A., Moore, R. H., & Domino, E. F. Correlation between brain N, N- dimethyltryptamine (DMT) levels and bar pressing behavior in rats: Effect of MAO inhibition. The Pharmacologist, 1974, 16, 237.Google Scholar
  54. Mandel, L. R. Dimethyltryptamine: Its biosynthesis and possible role in mental disease. In E. F. Domino and J. M. Dau (Eds.), Neurotransmitters Balances Regulating Behavior. Ann Arbor, Michigan, Edwards Bros., Inc., 1975, in press.Google Scholar
  55. Mandel, L. R., Rosegay, A., Walker, R. W., VandenHeuvel, W. J. A., & Rokach, J. 5-Methyl-tetrahydrofolate acid as a mediator in the formation of pyridoindoles. Science, 1974, 186, 741–743.PubMedCrossRefGoogle Scholar
  56. Mandel, L. R., Ahn, H. S., VandenHeuvel, W. J. A., & Walker, R. W. Indoleamine-N-methyl-transferase in human lung. Biochem. Pharmacol., 1972, 21, 1197–1200.PubMedCrossRefGoogle Scholar
  57. Mandel, L. R., Rosenzweig, S., & Kuehl, F. A., Jr. Purification and properties of indoleamine-N-methyltransferase. Biochem. Pharmacol., 1971, 20, 712–716.PubMedCrossRefGoogle Scholar
  58. Manowitz, P., Gilmour, D. G., & Racevskis, J. Low plasma tryptophan levels in recently hospitalized schizophrenics. Biol. Psychiat., 1973, 6, 109–118.PubMedGoogle Scholar
  59. Martin, W. R., Sloan, J. W., Christian, S. T., & Clements, T. H. Brain levels of tryptamine. Psychopharmacologia (Berl.), 1972, 24, 331–346.Google Scholar
  60. Moore, R. H., Demetriou, S., & Domino, E. F. Effects of iproniazid, chlorpromazine and methiothepin on DMT-induced changes in body temperature, pupil dilatation, blood pressure and EEG in the rabbit. Arch. Int. Pharmacol. et Dynamie., et de Ther., 1975, 213, 64–72.Google Scholar
  61. Murphree, H. B., Dippy, R. H., Jenney, E. H., & Pfeiffer, C. C. Effects in normal man of α-methyltryptamine and α-ethyltryptamine. Clin Pharmacol. Ther., 1961, 2, 722–726.PubMedGoogle Scholar
  62. Murphy, D. L., & Wyatt, R. J. Reduced monoamine oxidase activity in blood platelets from schizophrenic patients. Nature 1972, 238, 225–226.PubMedCrossRefGoogle Scholar
  63. Narasimhachari, N., Heller, B., Spaide, J., Haskovec, L., Fujimori, M., Tabushi, K., & Himwich, H. E. Urinary studies of schizophrenics and controls. Biol. Psychiat., 1971a, 3, 9–20.PubMedGoogle Scholar
  64. Narasimhachari, N., Heller, B., Spaide, J., Haskovec, L., Meltzer, H., Strahilevitz, M., & Himwich, H. E. N-N-Dimethylated indoleamines in blood. Biol. Psychiat., 1971b. 3, 21–23.PubMedGoogle Scholar
  65. Narasimhachari, N., Plaut, J. M., & Himwich, H. E. Indole ethylamine-N-methyltransferase in serum samples of schizophrenics and normal controls. Life Sci., 1972, 11, 221–227.CrossRefGoogle Scholar
  66. Rosenberg, D. E. Isbell, H., & Miner, E. J. Comparison of a placebo, N-dimethyltryptamine, and 6-hydroxy-N-dimethyltryptamine in man. Psychopharmacologia (Berl.), 1963, 4, 39–42.CrossRefGoogle Scholar
  67. Rosenberg, D. E., Isbell, H., Miner, E. J., & Logan, C. R. The effect of N, N-dimethyl-tryptamine in human subjects tolerant to lysergic acid diethylamide. Psychopharmacologia (Berl.), 1964, 5, 217–227.CrossRefGoogle Scholar
  68. Rosengarten, H., Szemis, A., Piotrowski, A., Romaszewska, K., Matsumato, H., Stencka, K., & Jus, A. N, N-Dimethyltryptamine and bufotenin in the urine of patients with chronic and acute schizophrenic psychoses. Psychiatria Polska, 1970, 4, 519–521.PubMedGoogle Scholar
  69. Rothlin, E. Pharmacology of lysergic acid diethylamide and some of its related compounds. In S. Garattini and V. Ghetti (Eds.), Psychotropic Drugs, Amsterdam: Elsevier, 1957, pp. 36–47.Google Scholar
  70. Saavedra, J. M., & Axelrod, J. Psychotomimetic N-methylated tryptamines: formation in brain in vivo and in vitro. Science, 1972, 172, 1365–1366.CrossRefGoogle Scholar
  71. Saavedra, J., Coyle, J. R., & Axelrod, J. The distribution and properties of the non-specific N-methyltransferase in brain. J. Neurochem., 1973, 20, 743–752.PubMedCrossRefGoogle Scholar
  72. Sai-Halász, A. The effect of antiserotonin on the experimental psychosis induced by dimethyltryptamine. Experentia (Basel), 1962a, 18, 137–138.CrossRefGoogle Scholar
  73. Sai-Halász, A. The role of serotonin antagonism in the model-psychoses. (Hung.) Iddeggyog-Szle, 1962b, 15, 301.Google Scholar
  74. Sai-Halász, A. The effect of MAO inhibition on the experimental psychosis induced by dimethyltryptamine. Psychopharmacologia (Berl.), 1963, 4, 385–388.PubMedCrossRefGoogle Scholar
  75. Schwartz, M. A., Aikens, A. M., & Wyatt, R. J. Monoamine oxidase activity in brains from schizophrenic and mentally normal individuals. Psychopharmacologia, 1974, 38, 319–328.PubMedCrossRefGoogle Scholar
  76. Seevers, M. H., & Deneau, G. A. Physiological aspects of tolerance and physical dependence. In W. S. Root and F. G. Hofmann (Eds.), Physiological Pharmacology, Vol. 1, Part A, New York: Academic Press, 1963, pp. 565–640.Google Scholar
  77. Shapiro, S. K., Almenas, A., & Thomson, J. F. Kinetics and mechanism of reaction of S-adenosylmethionine: homocysteine methyltransferase. J. Biol. Chem., 1965, 240, 2512–2518.PubMedGoogle Scholar
  78. Smythies, J. R. (Ed.). The Mode of Action of Psychotomimetic Drugs. A Report Based On An NRP Work Session. Neurosciences Research Program Bulletin, 1970, 8, 1, 152.Google Scholar
  79. Sourkes, T. L. Alpha-methyltryptophan and its actions on tryptophan metabolism. Fed. Proc, 1971, 30, 897–903.PubMedGoogle Scholar
  80. Sprince, H., Parker, C. M., Jameson, D., & Alexander, F. Urinary indoles in schizophrenic and psychoneurotic patients after administration of tranylcypromine (Parnate) and methionine or tryptophan. J. Nerv. Ment. Dis., 1963, 137, 246–251.PubMedCrossRefGoogle Scholar
  81. Swiatek, K. R., Simon, L. N., & Chao, K.-L. Nicotinamide methyltransferase and S-adenosyl-methionine: 51-methylthioadenosine hydrolase. Control of transfer ribonucleic acid methylation. Biochem., 1973, 12, 4670–4674.CrossRefGoogle Scholar
  82. Szara, S. Hallucinogenic effects and metabolism of tryptamine derivatives in man. Fed. Proc., 1961, 20, 285–288.Google Scholar
  83. Szara, S., & Axelrod, J. Hydroxylation and N-demethylation of N, N-dimethyltryptamine. Expenentia, 1959, 15, 216–217.CrossRefGoogle Scholar
  84. Szara, S., Hearst, E., & Putney, F. Metabolism and behavioral action of psychotropic tryptamine homologues. Int. J. Neuropharmacol., 1962, 1, 111–117.CrossRefGoogle Scholar
  85. Tedeschi, D. H., Tedeschi, R. E., & Fellows, E. J. The effects of tryptamine on the central nervous system, including a pharmacological procedure for the evaluation of iproniazid-like drugs. J. Pharmacol. Exp. Ther., 1959, 126, 223–232.PubMedGoogle Scholar
  86. Tenen, S. S. An automated one-way avoidance box for the rat. Psychonom. Sci., 1965, 6, 407–408.Google Scholar
  87. Vasko, M., Lutz, M. P., & Domino, E. F. Structure activity relations of some idolealkyamines in comparison to phenethylamines on motor activity and acquisition of avoidance behavior. Psychopharmacologia, 1974, 36, 49–58.PubMedCrossRefGoogle Scholar
  88. Walker, R. W., Ahn, H. S., Albers-Schonberg, G., Mandel, L. R., & VandenHeuvel, W. J. A. Gas chromatographic-mass spectrometric isotope dilution assay for N, N-dimethyltryptamine in human plasma. Biochem. Med., 1973, 8, 105–113.PubMedCrossRefGoogle Scholar
  89. Wise, C. D., Baden, M. M., & Stein, L. Postmortem measurement of enzymes in human brain: Evidence of a central noradrenergic deficit in schizophrenia. In E. F. Domino and J. Davis (Eds.), Neurotransmitter Balances Regulating Behavior, Ann Arbor, Michigan, Edwards Bros, Inc., 1975, in press.Google Scholar
  90. Wyatt, R. J., Vaughan, T., Galanter, M., Kaplan, J., & Green, R. Behavioral changes of chronic schizophrenic patients given L-5 hydroxytryptophan. Science, 1972, 177, 1124–1126.PubMedCrossRefGoogle Scholar
  91. Wyatt, R. J., Mandel, L. R., Ahn, H. S., Walker, R. W. & VandenHeuvel, W. J. A. Gas chromatographic-mass spectrometric isotope dilution determination of N, N-dimethyltryptamine concentrations in normals and psychiatric patients. Psychopharmacologia (Berl.), 1973a, 31, 265-270.Google Scholar
  92. Wyatt, R. J., Mandel, L. R., Ahn, H. S., Walker, R. W. & VandenHeuvel, W. J. A. DMT—a possible relationship to schizophrenia. Proc. 1st Intl. Serotonin Conference. 1973b, in press.Google Scholar
  93. Wyatt, R. J., Murphy, D. L., Belmaker, R., Donnelly, D., Cohen, S., & Pollin, W. Reduced monoamine oxidase activity in platelets: a possible genetic marker for vulnerability to schizophrenia. Science, 1973c, 179, 916-918.Google Scholar
  94. Wyatt, R. J., Saavedra, J. M., & Axelrod, J. A dimethyltrptamine (DMT) forming enzyme in human blood. Amer. J. Psychiat., 1973d, 130, 754–760.PubMedGoogle Scholar
  95. Yang, H. Y. T., & Neff, N. H. The monoamine oxidases of brain: selective inhibition with drugs and the consequences of the metabolism of the biogenic amines. J. Pharmacol. Esp. Ther., 1974, 189, 3, 733–740.Google Scholar
  96. Zappia, V., Zydek-Cwick, C. R., & Schlenk, F. The specificity of S-adenosylmethionine derivatives in methyl transfer reactions. J. Biol. Chem., 1969, 244, 4499–4509.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1976

Authors and Affiliations

  • Edward F. Domino
    • 1
    • 2
  1. 1.Department of PharmacologyLafayette ClinicDetroitUSA
  2. 2.University of MichiganAnn ArborUSA

Personalised recommendations